PE20210394A1 - Profarmacos de derivados de triazol sustituido y sus usos - Google Patents

Profarmacos de derivados de triazol sustituido y sus usos

Info

Publication number
PE20210394A1
PE20210394A1 PE2020000813A PE2020000813A PE20210394A1 PE 20210394 A1 PE20210394 A1 PE 20210394A1 PE 2020000813 A PE2020000813 A PE 2020000813A PE 2020000813 A PE2020000813 A PE 2020000813A PE 20210394 A1 PE20210394 A1 PE 20210394A1
Authority
PE
Peru
Prior art keywords
compounds
prevention
treatment
diseases
substitute
Prior art date
Application number
PE2020000813A
Other languages
English (en)
Inventor
Marie-Pierre Collin-Kroepelin
Peter Kolkhof
Thomas Neubauer
Chantal Fuerstner
Elisabeth Pook
Matthias Beat Wittwer
Carsten Schmeck
Pierre Wasnaire
Heiko Schirmer
Hana Cernecka
Karoline Droebner
Hanna Tinel
Anja Buchmueller
Thomas Mondritzki
Axel Kretschmer
Klemens Lustig
Robert Fricke
Guillaume Levilain
Ursula Krenz
Norbert Witowski
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of PE20210394A1 publication Critical patent/PE20210394A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Abstract

La presente invencion se refiere a compuestos de formula (I) o una de sus sales farmaceuticamente aceptables, donde R1 es de formula (a), (b) o (c); # representa el punto de union con el anillo 1,2,4-triazolilo. Tambien esta referida a procesos para la preparacion de tales compuestos y composiciones farmaceuticas. Un compuesto preferido: (2S)-3-[1-({5-Carbamoil-1-[3-(trifluorometil)piridin-2-il]-1H-1,2,4-triazol-3-il}metil)-3-(4- clorofenil)-5-oxo-1,5-dihidro-4H-1,2,4-triazol-4-il]-1,1,1-trifluoropropan-2-il fosfato 5 dihidrogeno. Tambien esta referida a procesos para la preparacion de tales compuestos, a composiciones farmaceuticas que contienen tales compuestos, y al uso de tales compuestos o composiciones para el tratamiento y/o prevencion de enfermedades, en particular para el tratamiento y/o prevencion de enfermedades renales y cardiovasculares. Dichos compuestos son utiles para el tratamiento y/o prevencion de enfermedades, en particular para el tratamiento y/o prevencion de enfermedades renales y cardiovasculares.
PE2020000813A 2017-10-24 2018-10-17 Profarmacos de derivados de triazol sustituido y sus usos PE20210394A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17197935 2017-10-24
PCT/EP2018/078364 WO2019081292A1 (en) 2017-10-24 2018-10-17 PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF

Publications (1)

Publication Number Publication Date
PE20210394A1 true PE20210394A1 (es) 2021-03-02

Family

ID=60162099

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000813A PE20210394A1 (es) 2017-10-24 2018-10-17 Profarmacos de derivados de triazol sustituido y sus usos

Country Status (38)

Country Link
US (1) US11298367B2 (es)
EP (1) EP3700913B1 (es)
JP (1) JP2021500365A (es)
KR (1) KR20200069361A (es)
CN (1) CN111225921A (es)
AR (1) AR113791A1 (es)
AU (1) AU2018356352A1 (es)
BR (1) BR112020007983A2 (es)
CA (1) CA3079767A1 (es)
CL (1) CL2020001076A1 (es)
CO (1) CO2020004945A2 (es)
CR (1) CR20200176A (es)
CU (1) CU24604B1 (es)
CY (1) CY1124938T1 (es)
DK (1) DK3700913T3 (es)
DO (1) DOP2020000076A (es)
EA (1) EA202091025A1 (es)
EC (1) ECSP20023056A (es)
ES (1) ES2906305T3 (es)
HR (1) HRP20220060T1 (es)
HU (1) HUE057278T2 (es)
IL (1) IL273949A (es)
JO (1) JOP20200099A1 (es)
LT (1) LT3700913T (es)
MA (1) MA50438B1 (es)
MX (1) MX2020004191A (es)
NI (1) NI202000030A (es)
PE (1) PE20210394A1 (es)
PH (1) PH12020550473A1 (es)
PL (1) PL3700913T3 (es)
PT (1) PT3700913T (es)
RS (1) RS62984B1 (es)
SG (1) SG11202003049WA (es)
SI (1) SI3700913T1 (es)
TW (1) TW201932117A (es)
UA (1) UA126456C2 (es)
UY (1) UY37948A (es)
WO (1) WO2019081292A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021259852A1 (en) 2020-06-25 2021-12-30 Bayer Aktiengesellschaft Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives
WO2022112213A1 (en) 2020-11-30 2022-06-02 Bayer Aktiengesellschaft Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
KR100854872B1 (ko) 2003-12-22 2008-08-28 화이자 인코포레이티드 바소프레신 길항제로서의 트리아졸 유도체
WO2005105779A1 (en) 2004-04-28 2005-11-10 Pfizer Limited 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
JP2011502982A (ja) * 2007-11-06 2011-01-27 アストラゼネカ・アクチエボラーグ 好中球エラスターゼの阻害剤としてのある種の２−ピラジノン誘導体およびその使用
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
AR076542A1 (es) * 2009-05-22 2011-06-22 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida
AU2011219746B2 (en) 2010-02-27 2015-04-23 Bayer Intellectual Property Gmbh Bisaryl-bonded aryltriazolones and use thereof
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CN106977530A (zh) 2010-07-09 2017-07-25 拜耳知识产权有限责任公司 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
MX2016004532A (es) * 2013-10-16 2016-07-22 Bayer Cropscience Ag Combinaciones de compuestos activos que comprenden un derivado de (tio)carboxamida y un compuesto fungicida.
CN107074783B (zh) 2014-11-03 2020-06-05 拜耳制药股份公司 羟烷基取代的苯基三唑衍生物及其用途
UY36571A (es) * 2015-03-05 2016-09-30 Bayer Cropscience Ag Combinaciones de compuestos activos
AR108265A1 (es) 2016-05-03 2018-08-01 Bayer Pharma AG Derivados de feniltriazol sustituidos con amida y usos de estos
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
WO2017191114A1 (en) 2016-05-03 2017-11-09 Bayer Aktiengesellschaft Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof
WO2017191105A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Amide-substituted aryltriazole derivatives and uses thereof
EP3452457B1 (en) 2016-05-03 2020-03-18 Bayer Pharma Aktiengesellschaft Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
US10525041B2 (en) 2016-05-03 2020-01-07 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
WO2018073144A1 (en) 2016-10-20 2018-04-26 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted triazole derivatives and uses thereof

Also Published As

Publication number Publication date
EP3700913B1 (en) 2021-11-10
CN111225921A (zh) 2020-06-02
CU20200040A7 (es) 2021-03-11
DK3700913T3 (da) 2022-02-07
LT3700913T (lt) 2022-01-25
JP2021500365A (ja) 2021-01-07
UA126456C2 (uk) 2022-10-05
AU2018356352A1 (en) 2020-04-16
MA50438A (fr) 2020-09-02
ES2906305T3 (es) 2022-04-18
MX2020004191A (es) 2020-08-03
WO2019081292A1 (en) 2019-05-02
UY37948A (es) 2019-05-31
BR112020007983A2 (pt) 2020-10-27
AR113791A1 (es) 2020-06-10
US20200338096A1 (en) 2020-10-29
CO2020004945A2 (es) 2020-05-05
PL3700913T3 (pl) 2022-02-21
PH12020550473A1 (en) 2021-03-08
PT3700913T (pt) 2022-01-31
US11298367B2 (en) 2022-04-12
NI202000030A (es) 2020-10-09
CR20200176A (es) 2020-07-24
SI3700913T1 (sl) 2022-02-28
CL2020001076A1 (es) 2021-02-19
CA3079767A1 (en) 2019-05-02
SG11202003049WA (en) 2020-04-29
DOP2020000076A (es) 2020-08-31
TW201932117A (zh) 2019-08-16
HRP20220060T1 (hr) 2022-04-15
CU24604B1 (es) 2022-06-06
EA202091025A1 (ru) 2020-07-30
RS62984B1 (sr) 2022-03-31
IL273949A (en) 2020-05-31
ECSP20023056A (es) 2020-12-31
HUE057278T2 (hu) 2022-04-28
MA50438B1 (fr) 2022-03-31
JOP20200099A1 (ar) 2020-05-06
EP3700913A1 (en) 2020-09-02
CY1124938T1 (el) 2023-01-05
KR20200069361A (ko) 2020-06-16

Similar Documents

Publication Publication Date Title
Kaur et al. Trifluoromethylpyrazoles as anti-inflammatory and antibacterial agents: A review
AR108265A1 (es) Derivados de feniltriazol sustituidos con amida y usos de estos
AR102487A1 (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
UY37220A (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos
CL2013003672A1 (es) Compuestos fungicidas de 1-(2-(2-halo-4-(4-halogen-fenoxi)-fenil)-2-alcoxi-2-ciclil-etil)-1h-(1,2,4)triazol sustituidos; procesos para preparar dichos compuestos; composicion agroquimica que la comprende; uso para combatir hongos fitopatógenos.
CL2014000384A1 (es) Compuestos fungicidas de 1-(2-(2-halo-4-(4-halogen-fenoxi)-fenil)-2-alcoxi-2-alquinil/alquenil-etil)-1h-(1,2,4) triazol sustituidos; proceso para preparar dichos compuestos; composiciones agroquímicas.
MX2020005818A (es) Triazol azoles de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa).
EA202090413A1 (ru) Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы
PE20210394A1 (es) Profarmacos de derivados de triazol sustituido y sus usos
MX2019012803A (es) Nuevos derivados de pirazol biciclicos.
MX2021011606A (es) Compuestos dirigidos a prmt5.
WO2007017126A3 (en) POLYMORPH OF N-PIPERIDINYL-5- (4-CHLOROPHENYL) -1- (2, 4-DICHLOROPHENYL) -4, 5-DIHYDRO-lH-PYRAZOLE- 3 -CARBOXAMIDE AND ITS USE AS A CAMNABINOID RECEPTOR MODULATOR
EP4249005A3 (en) 18f-labeled triazole containing psma inhibitors
MX2020011873A (es) Nuevos derivados de quinolina.
CL2022000129A1 (es) Derivados de triazol y pirazol plaguicidas
MX2020001323A (es) Metodos para tratar alteraciones del comportamiento.
EA201891467A1 (ru) Сокристалл, способ его получения и лекарственное средство, содержащее сокристалл
JOP20200133A1 (ar) طريقة لتحضير حمض (3s)-3-(4-كلورو-3-{[(2s،3r) -2-(4-كلورو فنيل) -4، 4، 4-ثلاثي فلورو-3-مثيل بيوتانويل] أمينو} فنيل) -3- بروبيل حلقي بروبانويك والشكل البلوري منه لاستخدامه كمركب فعال صيدلانياً
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
MX2021007258A (es) Composiciones de esparsentan amorfas.
PH12021550248A1 (en) Borate of azetidine derivative
MX2017008078A (es) Composiciones de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h-indazol-5- il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il)fenil)-3,6-dihidrop iridin-1(2h)-il)-2-oxoetil)-3-(metiltio)pirrolidin-3-carboxamida para preparaciones farmaceuticas.
AR103219A1 (es) Compuesto de (1h-indol-3-il)propan-1-ona, composición farmacéutica, combinación y mezcla que lo comprenden y su uso para la fabricación de un medicamento
MX2020003620A (es) Composiciones y métodos para usar cis-4-[2-{[(3s,4r)-3-fluorooxan- 4-il]amino}-8-(2,4,6-tricloroanilino)-9h-purin-9-il]-1-etilcicloh exano-1-carboxamida.
AR114231A2 (es) Compuesto de amida heterocíclico, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento